RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Boston, MA · +22 more sites
Breast Cancer clinical trials in Boston, MA
66 recruiting breast cancer studies with a site in Boston, MA.
RecruitingPhase 1NCT07137416
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Sponsor: National Cancer Institute (NCI)
Boston, MA · +1 more sites
RecruitingPhase 1NCT05111561
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Sponsor: National Cancer Institute (NCI)
Boston, MA · +2 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Boston, MA · Worcester, MA · +126 more sites
RecruitingPhase 1 / Phase 2NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor: Genmab
Boston, MA · +35 more sites
RecruitingPhase 1NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Sponsor: Eli Lilly and Company
Boston, MA · +14 more sites
RecruitingPhase 1NCT06840886
A Study of PHST001 in Advanced Solid Tumors
Sponsor: Pheast Therapeutics
Boston, MA · +19 more sites
RecruitingPhase 3NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Boston, MA · +50 more sites
RecruitingPhase 2NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Sponsor: Bayer
Boston, MA · +10 more sites
RecruitingNot applicableNCT07059884
Distance-Based Exercise to Preserve Function and Prevent Disability
Sponsor: Alliance for Clinical Trials in Oncology
Boston, MA · +22 more sites
RecruitingPhase 1NCT05877599
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Sponsor: AstraZeneca
Boston, MA · +18 more sites
RecruitingPhase 1NCT07578571
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Sponsor: Immunome, Inc.
Boston, MA · +3 more sites
RecruitingPhase 3NCT05646862
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Sponsor: Hoffmann-La Roche
Boston, MA · +38 more sites
RecruitingPhase not listedNCT06094257
Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients
Sponsor: Weill Medical College of Cornell University
Boston, MA · +1 more sites
RecruitingNot applicableNCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Boston, MA · +48 more sites
RecruitingPhase 1NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Sponsor: SystImmune Inc.
Boston, MA · +20 more sites
RecruitingPhase 2NCT06923527
Circulating Tumor DNA
Sponsor: Yale University
Boston, MA · +6 more sites
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Boston, MA · +173 more sites
RecruitingPhase not listedNCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Sponsor: Guardant Health, Inc.
Boston, MA · +32 more sites
RecruitingPhase 1 / Phase 2NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Sponsor: Gilead Sciences
Boston, MA · +11 more sites
RecruitingPhase 2NCT04899908
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Sponsor: Brigham and Women's Hospital
Boston, MA
RecruitingPhase 3NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor: NRG Oncology
Beverly, MA · Boston, MA · +1223 more sites
RecruitingPhase 1NCT06488378
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Sponsor: Dana-Farber Cancer Institute
Boston, MA · +1 more sites
RecruitingPhase not listedNCT06888388
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Boston, MA · +4 more sites
RecruitingPhase 1NCT07182149
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Sponsor: Normunity AccelCo, Inc.
Boston, MA · +16 more sites
RecruitingNot applicableNCT07482384
Supporting Health Including Endocrine Treatment for Long Duration
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase 3NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Sponsor: Greenwich LifeSciences, Inc.
Boston, MA · +50 more sites
RecruitingPhase 2NCT06439693
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Boston, MA · +825 more sites
RecruitingPhase 3NCT06748222
E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
Beverly, MA · Boston, MA · Burlington, MA · +378 more sites
RecruitingPhase 1NCT06562192
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Sponsor: Novartis Pharmaceuticals
Boston, MA · +8 more sites
RecruitingPhase 2NCT06184750
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Sponsor: National Cancer Institute (NCI)
Boston, MA · +9 more sites
RecruitingPhase 2NCT02896335
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Sponsor: Massachusetts General Hospital
Boston, MA
RecruitingPhase 2NCT05467891
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Sponsor: Oana Danciu
Boston, MA · +20 more sites
RecruitingPhase not listedNCT05142800
Screening For BCRL In Targeted Therapy For Breast Cancer
Sponsor: Massachusetts General Hospital
Boston, MA
RecruitingPhase 1 / Phase 2NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Boston, MA · +26 more sites
RecruitingPhase 1NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Boston, MA · +103 more sites
RecruitingPhase not listedNCT07675967
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Sponsor: Dana-Farber Cancer Institute
Boston, MA
RecruitingPhase 1NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Sponsor: Eli Lilly and Company
Boston, MA · +14 more sites
RecruitingPhase 3NCT05696626
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Sponsor: LeonaBio
Boston, MA · +33 more sites
RecruitingPhase 1 / Phase 2NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Sponsor: Kristina A. Fanucci
Boston, MA
RecruitingNot applicableNCT05890677
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
Sponsor: University Hospital, Basel, Switzerland
Boston, MA · +3 more sites
RecruitingPhase 2NCT04434040
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Sponsor: Dana-Farber Cancer Institute
Boston, MA · +6 more sites
RecruitingPhase 1 / Phase 2NCT05608252
VS-6766+Abema+Fulv in Met HR+/HER- BC
Sponsor: Adrienne G. Waks
Boston, MA
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Boston, MA · Lowell, MA · +810 more sites
RecruitingPhase not listedNCT03448926
The PREDICT Registry:
Sponsor: PreludeDx
Boston, MA · +29 more sites
RecruitingPhase 2NCT06042569
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Sponsor: City of Hope Medical Center
Boston, MA · +2 more sites
RecruitingPhase 1 / Phase 2NCT05785741
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
Boston, MA · +14 more sites
RecruitingPhase not listedNCT02610413
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Sponsor: National Cancer Institute (NCI)
Boston, MA
RecruitingPhase not listedNCT02610426
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
Sponsor: National Cancer Institute (NCI)
Boston, MA
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.